NCCN 2024 Nursing Program: Advancing Oncology Nursing™

April 4, 2024

This program will provide oncology nurses with comprehensive and clinically relevant information to optimize patient education and care. Presentations will focus on current and critical issues to provide oncology nurses with practical information that can be implemented in the practice setting.

Target Audience

This program is designed to meet the educational needs of oncology nurses who manage patients with cancer.

Learning Objectives

Following this program, participants should be able to:

Overall Learning Objectives
•   Discuss advances in the treatment of patients with cancer and key updates in the NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines®) and apply appropriate treatment and supportive care strategies to optimize patient education and care.
•   Review issues related to Updates on Safe Handling; A Model for Responding to Chemotherapy Infusion Hypersensitivity Reactions; Management of Colorectal Cancer; Bispecific Antibodies: A New Frontier in Immunotherapy; Current Treatment Approaches for Transformed Indolent B-Cell Lymphomas; Pain Management in Oncology; and Cancer Care of the LGBTQ+ Community: Nursing Perspectives.

Updates on Safe Handling
•   Review the health risks for nurses associated with handling hazardous drugs.
•   Discuss the current standards for the safe handling of hazardous drugs.
•   Identify barriers to nursing compliance with safe handling standards.

A Model for Responding to Chemotherapy Infusion Hypersensitivity Reactions
•   Review the incidence, clinical features and complications associated with hypersensitivity reactions.
•   Discuss best practices in the management of hypersensitivity reactions.
•   Discuss the implementation of a hypersensitivity algorithm and the practice implications.

Management of Colorectal Cancer
•   Describe the importance of diagnostic evaluation and impact on treatment approaches.
•   Summarize new advancements in the management of colorectal cancer.
•   Provide examples of supportive care issues and related interventions for patients with colorectal cancers.

Bispecific Antibodies: A New Frontier in Immunotherapy
•   Discuss the unique function of bispecific antibodies.
•   Review symptom management of recently approved agents.
•   Provide common challenges with coordination of care and logistics with these agents.

Current Treatment Approaches for Transformed Indolent B-Cell Lymphomas
•   Outline the current treatment approach for transformed indolent lymphomas.
•   Summarize the evidence from clinical trials supporting the use of CAR T-cell therapy and other novel chemotherapy-free options for the management of transformed indolent lymphomas.
•   Review the unique toxicities associated with novel agents including CAR T-cell therapy and develop an effective supportive care plan for the prevention and management of treatment-related side effects.

Pain Management in Oncology
•   Describe the role of non-opioid analgesics in the management of cancer pain.
•   Review the principles and utilization of opioids in moderate to severe cancer pain.
•   Elaborate on medical management strategies of opioid-induced adverse effects.

Cancer Care of the LGBTQ+ Community: Nursing Perspectives
•   Review the incidence of cancer in the LGBTQ+ patient population.
•   Discuss the barriers to care for LGBTQ+ patients.
•   Identify nursing competencies to improve the care of LGBTQ+ patients experiencing cancer.

You may also be interested in

Supportive Oncology Care

Many health care professionals have had limited education on supportive care topics and have learned on the job. The guidelines and literature continue to advance supportive oncology care.
Additional information
Supporters: 

Supported by an independent medical education grant from ADC Therapeutics.
Supported by a grant from Pfizer Inc.
Supported by an independent educational grant from Incyte Corporation.
Supported by an educational grant from Genentech, a member of the Roche Group.

Course summary
Available credit: 
  • 5.25 ANCC contact hours
    • 3.50 ANCC Pharmacology Contact Hours
  • 5.25 Participation
Course opens: 
04/02/2024
Course expires: 
07/31/2024
Event starts: 
04/04/2024 - 8:00am EDT
Event ends: 
04/04/2024 - 3:00pm EDT
Cost:
$0.00
Add to calendar: 

NCCN Continuing Education Disclosure Policy
It is the policy of NCCN that all planners, faculty, moderators, authors, reviewers and anyone involved in the planning and delivery of NCCN continuing education activities are expected to disclose ALL financial relationships they have had in the past 24 months with ineligible companies. The ACCME Standards for Integrity and Independence require that individuals who refuse to provide this information will be disqualified from involvement in the planning and implementation of accredited continuing education presented by NCCN. NCCN identifies, mitigates and discloses to learners all relevant financial relationships.

In addition, all content has been reviewed to ensure education promotes safe, effective patient care and does not promote the products or services of an ineligible company. Content, including any presentation of therapeutic options, is fair, balanced, evidence-based, scientifically accurate, and free of commercial bias and marketing. 

Definitions  

Ineligible Company: An ineligible company is any entity whose primary business is producing, marketing, selling, re-selling, or distributing healthcare products used by or on patients. 

Relevant Financial Relationships: Financial relationships of any dollar amount occurring within the past 24 months are defined as relevant if the educational content an individual can control is related to the business lines or products of an ineligible company. There is no minimum financial threshold. We ask for disclosure of ALL financial relationships with ineligible companies, regardless of the amount and regardless of the potential relevance of each relationship to the education.

Faculty Disclaimers  

All faculty for this continuing education activity are competent in the subject matter and qualified by experience, training, and/or preparation for the tasks and methods of delivery.

Faculty presentations may include discussion of off-label use. Faculty will disclose that the use in question is not currently approved by the FDA per the product labeling or marketing.

Faculty Disclosures

The faculty listed below have no relevant financial relationships with ineligible companies to disclose.

Robin R. Klebig, MSN, APRN, AOCNP
Marylou Nesbitt, MS, RN, AOCN
Carey Ramirez, ANP-C, ACHPN
Diego Rodriguez, MSN, RN, OCN
Kaylee Timlin, MSN, RN, AGACNP-BC
Amanda E. Visnick, RN, BSN, OCN

The faculty listed below have the following relevant financial relationship(s) with ineligible companies to disclose. All of the relevant financial relationships listed for these individuals have been mitigated. 

Megan Corbett, MSN, RN, NPD-BC, OCN 
PHARMACOSMOS A/S: Honoraria 

MiKaela M. Olsen, DNP, APRN-CNS, AOCNS, FAAN 
BD Biosciences: Consulting Fee; Honoraria 

Aileen Tangonan MacAndrew, RN, MSN, NP-C 
Taiho Pharmaceuticals Co., Ltd.: Product/Speakers Bureau 

NCCN Staff Disclosures

None of the other planners for this educational activity have relevant financial relationship(s) to disclose with ineligible companies whose primary business is producing, marketing, selling, re-selling, or distributing healthcare products used by or on patients.

In support of improving patient care, National Comprehensive Cancer Network (NCCN) is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.

Nurses
NCCN designates this educational activity for a maximum of 5.25 contact hours.

This program offers 3.5 pharmacotherapeutic contact hours for nurses. Eligible sessions are: 

  • Updates on Safe Handling
  • A Model for Responding to Chemotherapy Infusion Hypersensitivity Reactions
  • Management of Colorectal Cancer
  • Bispecific Antibodies: A New Frontier in Immunotherapy
  • Current Treatment Approaches for Transformed Indolent B-Cell Lymphomas

Available Credit

  • 5.25 ANCC contact hours
    • 3.50 ANCC Pharmacology Contact Hours
  • 5.25 Participation

Price

Cost:
$0.00
Please login or register to take this course.

Click the Take Course button to start the credit claiming process.
You must be logged in with the same email address used for program registration.

CE credit should be claimed for the program as a whole, not session by session. You may claim credit for the program only one time. When calculating your total credits, you should take into account all of the sessions you viewed either live or via recording. (Please note that you have access to all of the session recordings for 60 days following the live program.) 

Required Hardware/software

To complete this activity, users will need:

  • A device with an Internet connection and sound playback capability
    • One of the two latest versions of Google Chrome, Mozilla Firefox, or Safari
    • Internet Explorer is no longer supported
  • Adobe Reader or other PDF reader software for certificate viewing/printing